swissnex Brazil and Oswaldo Cruz Institute sign up Memorandum of Understanding

The centenary Fiocruz Castle (Fundacao Oswaldo Cruz Institute) was the grand setting for the formalization of the partnership between swissnex Brazil and one of the most important scientific institutions in the health area, the Oswaldo Cruz Institute. The signing of the Memorandum of Understanding took place in the room that was once the laboratory of Adolpho Lutz, an important Brazilian scientist (1855-1940). The initiative aims to bring Brazil and Switzerland closer together in the areas of Life Sciences, HealthTech and biotechnology not only in the academic field but also to foster science-based innovation and entrepreneurship.

One of the first actions, in the first half of 2019, will be an event focused on the Academia, Innovation and Training axes, providing debate and scientific training, with an approach to entrepreneurship. swissnex Brazil will work on prospecting and articulating partnerships with Swiss institutions in the areas of biotechnology and HealthTech and MedTech. The agreement was signed by swissnex Brazil CEO Maria Conti and IOC director José Paulo Gagliardi Leite.

About the Oswaldo Cruz Institute

Created in 1900, the Oswaldo Cruz Institute (IOC) is the germinal unit of the Oswaldo Cruz Foundation (Fiocruz), attached to the Brazilian Ministry of Health. One of the main biomedical research centers in Brazil, the Institute is responsible for a variety of scientific activities, always marked by the centenary commitment to do research allied to Education, to Reference in Health and to the maintenance of Biological Collections. Plural and contemporary, the Institute combines the tradition of decades of work dedicated to Brazil and Brazilians with the enthusiasm of those who still have much to contribute.

IOC maintains its commitment to produce relevant knowledge to Brazil and to contribute to global health. For this, the Institute deals with the study of a wide range of health issues and uses the most varied approaches. Its Research Laboratories generate knowledge on several aspects in a variety of infection diseases – AIDS, tuberculosis, malaria, yellow fever, dengue fever, Zika, Chagas disease, leishmaniasis, leptospirosis, hepatitis, leprosy, meningitis, among many others – as well as chronic degenerative diseases such as muscular dystrophy and behavioral disorders.

The Institute also takes part in environmental studies, prospecting of pharmaceuticals and development of new vaccines, diagnostic methods and therapeutic strategies, always aiming at responding to the challenges of public health issues in Brazil.